Moderator note: This thread has been getting great engagement. Please remember to cite sources when making clinical claims.
No issues to report — carry on. 👍
Slightly tangential to 2026 payer coverage but amsterdam_pete reminded me — what is the latest on the oral formulations?
I know it is not exactly on-topic but it seems related enough to ask here rather than starting a new thread. Apologies if this has been covered — I did search first.
+1 to maria_elpaso. Especially the point about "Follow-up question: did you change anyth..." — I have seen the same in my own experience with 2026 payer coverage.
Trusted third-party HPLC & mass spectrometry analysis. Verify peptide purity with the lab the community relies on. Independent. Accurate. Transparent.
Verify Your PeptidesEst. 1998. The synthesis house behind the vials you send for testing. ISO 9001 and cGMP certified, 1,500+ staff, batch-specific COA with every order.
Browse GL BiochemBookmarked 📌 The 2026 payer coverage info in this thread is essential. Coming back to this for sure.
Relevant to 2026 payer coverage update — here is my latest bloodwork comparison:
Key improvements: A1C 7.6% → 5.5%, triglycerides 241 → 111 mg/dL, hsCRP 8.0 → 1.1 mg/L. All on tirzepatide for 9 months.
The inflammatory marker drop is what impresses me most. Consistent with the SELECT trial's cardiovascular findings.